Abstract
Background: There are no published guidelines for the pharmacological management of insomnia in the pediatric population, and there are no Food and Drug Administration (FDA) approved medications for this purpose. Yet, many classes of psychopharmacological medications are used off-label in children and adolescents.
Objective: To describe the side effects of different classes of medications used as sleep aids in the pediatric population, and management of those side effects.
Method: Literature review and summary of existing evidence.
Results: Several medications used as pediatric sleep aids have side effects that range from inconvenient constitutional symptoms, major systemic cardiac, endocrinological and neurological symptoms to potentially fatal syndromes.
Conclusion: Clinicians need to be vigilant for adverse effects of these medications and to implement strategies to mitigate some of the effects, while educating patients and families about the pros and cons of medication use for insomnia.
Keywords: Insomnia, children and adolescents, psychopharmacology, side effects, medications, endocrinological and neurological symptoms.
Current Psychopharmacology
Title:Management of Adverse Effects of Sleep Medications in Pediatrics
Volume: 7
Author(s): Neelkamal Soares*Shibani Kanungo
Affiliation:
- Department of Pediatric and Adolescent Medicine, Western Michigan University Homer Stryker School of Medicine, Kalamazoo, MI, 49008,United States
Keywords: Insomnia, children and adolescents, psychopharmacology, side effects, medications, endocrinological and neurological symptoms.
Abstract: Background: There are no published guidelines for the pharmacological management of insomnia in the pediatric population, and there are no Food and Drug Administration (FDA) approved medications for this purpose. Yet, many classes of psychopharmacological medications are used off-label in children and adolescents.
Objective: To describe the side effects of different classes of medications used as sleep aids in the pediatric population, and management of those side effects.
Method: Literature review and summary of existing evidence.
Results: Several medications used as pediatric sleep aids have side effects that range from inconvenient constitutional symptoms, major systemic cardiac, endocrinological and neurological symptoms to potentially fatal syndromes.
Conclusion: Clinicians need to be vigilant for adverse effects of these medications and to implement strategies to mitigate some of the effects, while educating patients and families about the pros and cons of medication use for insomnia.
Export Options
About this article
Cite this article as:
Soares Neelkamal *, Kanungo Shibani , Management of Adverse Effects of Sleep Medications in Pediatrics, Current Psychopharmacology 2018; 7 (1) . https://dx.doi.org/10.2174/2211556007666180131153440
DOI https://dx.doi.org/10.2174/2211556007666180131153440 |
Print ISSN 2211-5560 |
Publisher Name Bentham Science Publisher |
Online ISSN 2211-5579 |
Call for Papers in Thematic Issues
Breakthroughs in drug design, development and delivery system for the management of neuro-psychiatric disorders
Neuropsychiatric diseases are one of the main causes of disability, affecting millions of people. Various drugs are used for its treatment, although no effective therapy has been found yet. The blood brain barrier (BBB) significantly complicates drugs delivery to the target cells in the brain tissues. This proposal describes the ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
What Can Neuroscience Tell Us About the Potential of Psychedelics in Healthcare? How the Neurophenomenology of Psychedelics Research Could Help us to Flourish Throughout Our Lives, as Well as to Enhance Our Dying
Current Drug Abuse Reviews Overlapping the Tryptophan Catabolite (TRYCAT) and Melatoninergic Pathways in Alzheimer's Disease
Current Pharmaceutical Design Enhancing Evidence Based Practice Implementation: Defining, Training and Evaluating Therapist Competence at Treating Youth Psychiatric Disorders
Adolescent Psychiatry Gene Expression and Regulation of Higher Plants Under Soil Water Stress
Current Genomics Hospital Exemption for Advanced Therapy Medicinal Products: Issue in Application in the European Union Member States
Current Stem Cell Research & Therapy Role of Nitric Oxide Signaling Pathways in Brain Injuries
Current Chemical Biology New Trends in Medicinal Chemistry Approaches to Antiobesity Therapy
Current Topics in Medicinal Chemistry The Role of Tai Chi in Mental Health Management—Lessons Learned from Clinical Trials
Reviews on Recent Clinical Trials 2-Aminoimidazole, Glycociamidine and 2-Thiohydantoin-Marine Alkaloids as Molecular Inspirations for the Development of Lead Structures
Current Drug Targets Current and Promising Therapies in Autosomal Recessive Ataxias
CNS & Neurological Disorders - Drug Targets Hypoxia-Inducible Factor-1α Contributes to Brain Edema after Stroke by Regulating Aquaporins and Glycerol Distribution in Brain
Current Neurovascular Research Relationship Between the Chemokine Receptor CCR5 and Microglia in Neurological Disorders: Consequences of Targeting CCR5 on Neuroinflammation, Neuronal Death and Regeneration in a Model of Epilepsy
CNS & Neurological Disorders - Drug Targets Concise Synthesis of Non-Protein Amino Acid from Natural Product via Schmidt Reaction
Letters in Organic Chemistry Muscle Atrophy Classification: The Need for a Pathway-Driven Approach
Current Pharmaceutical Design Role and Treatment of Mitochondrial DNA-Related Mitochondrial Dysfunction in Sporadic Neurodegenerative Diseases
Current Pharmaceutical Design Ghrelin and Motilin in the Gastrointestinal System
Current Pharmaceutical Design Mitochondrial Toxins in Basal Ganglia Disorders: From Animal Models to Therapeutic Strategies
Current Neuropharmacology Statin-Like Drugs for the Treatment of Brain Cholesterol Loss in Alzheimers Disease
Current Drug Safety A New Era of Pulmonary Delivery of Nano-antimicrobial Therapeutics to Treat Chronic Pulmonary Infections
Current Pharmaceutical Design Leptin and the Ob-Receptor as Anti-Obesity Target: Recent In Silico Advances in the Comprehension of the Protein-Protein Interaction and Rational Drug Design of Anti- Obesity Lead Compounds
Current Pharmaceutical Design